usd aug pm et
summari develop manufactur distribut continu glucos monitor system
nm price-to-earnings oper ep
risk assess reflect fact
produc sell one product although compani
littl debt yet gener annual net incom
compani face formid competit much
larger compani primarili
fiscal year end dec ep estim base cfra
oper earn histor earn report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
may stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
et cfra reiter
lift target
base discount cash flow
model ep vs surpass
estim lift ep
ep
million exceed expect led
 revenu growth intern
growth dxcm revenu growth
continu driven strong new patient
addit reach record level
awar real-tim continu glucos
monitor increas expect
sale grow vs
prior expect re-affirmed
timelin next gener cgm
work verili limit
launch late full launch
compani also reconfirm expect
exit gross margin almost
low rang driven
primarili lower cost transmitt
overal solid quarter /kevin
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
overview found aim address need diabet design
manufactur market continu glucos monitor cgm product potenti
enabl peopl diabet achiev sustain glycem control would help reduc
diabetes-rel health issu intern diabet feder estim million adult
year age live diabet number rise million
receiv approv first gener cgm
march receiv fda approv gener cgm call
signific enhanc predecessor elimin need finger stick
calibr confirm blood glucos level second cgm without finger stick
approv fda first freestyl libr flash approv
six month prior aim commerci introduc next gener devic late
earli incorpor verili alphabet research organ involv
object becom lead provid cgm system relat product compani
focus develop commerci product integr cgm technolog insulin deliveri
system partner dxcm partner insulin deliveri includ tandem
busi segment one oper segment compani primarili focus
design develop commerci cgm system primarili deriv revenu
fiscal unit state revenu outsid grew year-over-year
reach million fy million fy percentag total revenu revenu
outsid increas fy fy fy
competit landscap market blood glucos monitor devic highli competit
constantli chang substanti impact introduct new product enhanc
sell platinum mobil system compet directli larg conglomer
roch diagnost johnson johnson abbot laboratori panason healthcar hold
also manufactur market product single-point finger stick devic collect
compani make global sale self-monitor glucos test system regard
short-term continu intermitt flash glucos monitor devic primarili compet
inc
collabor agreement verili life scienc research organ jointli
develop seri next-gener cgm product see aggress explor extend
product portfolio categori peopl diabet includ type diabet
non-insulin use peopl pre-diabet peopl obes
merger acquisit made recent signific acquisit
trend revenu grow rapidli year end
compani five-year compound annual growth rate compound-annual-growth-rate year-over-year revenu growth
invest heavili research develop spent averag
revenu compani gener maintain net cash posit
howev achiev first year profit normal basi
senior vice presid
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
bullish sinc june technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
neutral continu expect compani
sub-industri achiev robust organ
growth posit macroeconom environ
compani gener benefit new
product launch laxer food drug
administr fda technolog advanc
sub-industri also mani product area
histor recession-resist
equip use non-elect procedur
howev valuat health care equip
compani elev rel
composit suggest posit
fundament reflect share
think higher valuat
sub-industri mostli warrant
strong recent margin expans revenu
growth associ robust product
expect sub-industri earn rise
high-single-digit percentag driven
continu pipelin innov new product
emerg market expans speed
new product come market
increas recent year
success effort fda reduc
approv time medic devic
time see price pressur incess
headwind medic equip compani
impact china-u trade war appear
insignific far medic
equip compani especi sinc
base medic equip manufactur
sourc insignific amount product
input china addit
chines govern seek lower health
care cost provid better health care
insul medic equip
sub-industri mount trade tension
larg medic equip target
chines tariff mean certain
compani
like
hurt trade tension howev bigger
concern medic equip
manufactur potenti trade
tension caus signific slowdown
possibl threat state american
health care system lawsuit texa
rule unconstitut
current expect upheld upon
appeal although decis could take
coupl year reach democrat
took control hous repres
period think
see substanti effort
republican trump administr
tri repeal
anoth legisl issu could impact
medic equip manufactur
potenti return medic devic tax
medic devic tax suspend
end congress fail
repeal suspend tax medic
devic manufactur could significantli
gener see posit long-term
fundament includ increas global
demand cost-effect value-bas
health care age popul rise
outlay result steadi flow
innov product revenu growth
year-to-d june
vs increas valu
 composit index
vs declin composit
base index
five-year market price perform aug
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
lift target base discount
cash flow model assum five-year forward compound annual growth rate
revenu ep vs higher
estim rais ep estim ep
estim sale increas year-over-year
million includ first full quarter sale recent launch
continu glucos monitor cgm sale grew year-over-year
million intern revenu grew million
think could achiev revenu growth vs origin
expect growth albeit lower margin custom mix shift
toward medicar intern market continu invest heavili
develop second gener devic track commerci releas
earli /kevin huang cfa
et cfra upgrad opinion share inc hold
sell rais target base
discount cash flow model suggest trade near fair
valu ep vs higher estim
lower ep rais ep
sale increas year-over-year million driven
primarili sale continu glucos monitor cgm launch
happen week origin expect revenu
growth high-end manag guidanc growth
stellar think could grow albeit
substanti lower margin compani priorit meet custom demand
manufactur effici believ impact launch
freestyl libr cgm instead pressur sale
anticip boost overal awar demand cgm technolog /kevin
analyst research note compani news
et cfra reiter hold opinion share inc
lift target base discount cash
flow model ep vs surpass estim
lift ep ep
sale increas year-over-year million exceed expect led
 revenu growth intern growth dxcm
revenu growth continu driven strong new patient addit
reach record level awar real-tim continu glucos monitor
increas expect sale grow vs
prior expect re-affirmed timelin next gener
cgm work verili limit launch late
full launch compani also reconfirm expect
exit gross margin almost low rang
driven primarili lower cost transmitt overal solid
et cfra reiter hold opinion share inc
cut target base dcf model
ep vs exceed consensu estim
strong sale volum growth increas global awar benefit
real-tim continu glucos monitor lift ep
ep sale increas year-over-year
million significantli exceed expect -- led growth
intern revenu follow growth revenu
lift revenu guidanc high end previou guidanc
compani lower expect gross oper margin due
stronger-than-expect price headwind howev expect margin weak
temporari introduct new transmitt autom
manufactur enabl exit year gross margin nearli
roughli basi point anticip full-year gross margin
et cfra keep hold opinion share inc
lift target base discount cash flow
model ep vs substanti exceed estim
higher-than-expect oper leverag rais ep
initi ep sale increas
year-over-year million sale growth
million intern sale growth million continu
anticip late earli launch next gener
continu glucos monitor cgm incorpor verili
alphabet research organ involv aim doubl
manufactur capac keep cgm demand adopt cgm
technolog continu grow rapid pace despit expect price headwind
due payer mix shift expect increas sale volum higher oper
leverag drive margin improv /kevin huang cfa
pm et cfra maintain sector
marketweight today first day annual jpmorgan
healthcar confer mani health care compani present
share drug maker alnylam pharmaceut neurocrin
bioscienc surg
intra-day manag care compani
also winner today increas share valu continu glucos
monitor cgm manufactur saw share rise
behemoth one large-cap health care
name today see plung share valu declin intra-day
weaker forward-look tone healthcar confer end januari
cfra expect see signific stock movement next
day compani continu provid updat outlook /kevin
et cfra keep hold opinion share inc
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd
repres total revenu estim
fiscal year analyst estim earn
per share grow usd
total
estimate estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
